Related Experiment Video
Updated: May 15, 2025

A Novel Vertebral Stabilization Method for Producing Contusive Spinal Cord Injury
Published on: January 5, 2015
Conservative and newer drug treatment for degenerative cervical myelopathy
Osita Ede1,2, Jason Pui Yin Cheung1
1Department of Orthopaedics and Traumatology, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
Abstract:
Degenerative cervical myelopathy (DCM) is the most common cause of non-traumatic spinal cord dysfunction in adults worldwide. Conservative treatments, such as physical therapy, activity modification, cervical traction, and the use of cervical collars, have been employed primarily for symptomatic relief in mild cases or for patients deemed unfit for surgery. Advances in our understanding of the molecular pathways involved in neuroinflammation and neuronal injury in DCM have spurred the development of newer pharmacological treatments aimed at neuroprotection and inflammation control. We found limited evidence that conservative treatment enhances functional recovery in patients with DCM. Patients with mild DCM who opt for conservative therapy should be aware of likely neurological deterioration and higher spinal cord injury risk following neck trauma. Nonoperative management could benefit patients with mild DCM who presented early (at least less than a year), have soft disc herniation as the cause of the myelopathy, have one level of myelopathic compression, and whose MRI does not show circumferential compression of the spinal cord. Riluzole did not replicate its promising animal results in human trials, using the modified Japanese Orthopaedic Association (mJOA) score as an outcome measure. Cerebrolysin is promising but needs more RCTs to define its role in the management algorithm. Limaprost Alfadex provided inconclusive evidence, however, is in an ongoing phase III trial. Erythropoietin showed benefit in animal and human trials but concerns over side effects may limit use. G-CSF demonstrated evidence of preserved neurological function in mice but needs human studies. Steroids did not show benefit and are likely deleterious to tissue healing and can increase infection risk. Anti-Fas ligand antibody has not been studied in humans but demonstrated benefit in animal models. Research should focus on large-scale RCTs for these drugs with careful attention to long-term effects, side effects, and finding the most effective doses.
Related Concept Videos
Skeletal Muscle Relaxants: Therapeutic Uses
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...

